Upstream Bio Business Summary

Upstream Bio, Inc. (UPB) is a clinical-stage biotechnology company that operates on a research-and-development business model, currently generating revenue primarily through interest income and potential milestone-based licensing rather than commercial product sales. The company’s primary business segments are focused on the development of verekitug (UPB-101), a novel monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor to treat severe inflammatory diseases. Its clinical pipeline is segmented into three major respiratory indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). Upstream Bio competes directly with industry giants such as Amgen/AstraZeneca (Tezspire), Sanofi/Regeneron (Dupixent), and GSK (depemokimab). The company differentiates itself as the only player with a clinical-stage TSLP receptor antagonist, positioning verekitug as a potentially best-in-class therapy offering superior dosing convenience (quarterly or semi-annual) compared to the monthly administration of current market leaders. Founded in 2021 by Eran Perry and Oren Becker, Upstream Bio is led by a management team with deep pedigree in pulmonary and inflammatory drug development. CEO Rand Sutherland, MD, previously served as CEO of Seeker Biologics and President of Translate Bio, while Chief Technology Officer Stacy Price, MS, PMP, joined in 2025 following senior roles at Invivyd and Akouos. The leadership team also includes CFO/COO Mike Gray, formerly of Curis, and CMO Aaron Deykin, MD, who led immunology development at Biogen. The company is backed by a high-profile board chaired by Ronald C. Renaud, Jr. (CEO of Kailera Therapeutics and former CEO of Cerevel) and includes representatives from premier life science investors such as OrbiMed, Venrock, and Access Industries. Following its 2024 IPO, the company maintains a robust capital position supported by institutional investors including Patient Square Capital, Decheng Capital, and Bain Capital Life Sciences.